Literature DB >> 11821625

Immune and neurohormonal pathways in chronic heart failure.

Rakesh Sharma1, Stefan D Anker.   

Abstract

Chronic heart failure is a complex disorder with interactions among the cardiovascular, immune, and neurohormonal systems. The concept that the progression of heart failure is due to neurohormonal abnormalities has received the greatest attention to date, leading to substantial therapeutic benefits. Although many current therapies are also thought to exert a variety of immunologic effects, this has been much less studied. In this review, the authors discuss a number of interactions among immune pathways and neurohormonal abnormalities relevant to heart failure. Cytokines, in particular tumor necrosis factor-alpha, have tremendous interactive opportunities within a regulatory network of energy metabolism, immune function, and neuroendocrine and hormonal function. Inflammatory cytokines are known to contribute to the progression of heart failure, and have been related to patients' prognosis. Advanced heart failure can be considered a state of chronic (low-grade) inflammation, and there are many reasons to suggest that anticytokine therapy could be successful in these patients. These novel approaches are certainly not without some risk, and many of them are very expensive, which may limit their application to certain subgroups of patients. In the future, it may not be enough to monitor cardiac function alone. Rather, the immune and neurohormonal status of patients may also need to be included in the performance of a complete assessment. (c)2002 CHF, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11821625     DOI: 10.1111/j.1527-5299.2002.00724.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  7 in total

1.  Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure.

Authors:  Bo Ding; Jun-Ichi Abe; Heng Wei; Qunhua Huang; Richard A Walsh; Carlos A Molina; Allan Zhao; Junichi Sadoshima; Burns C Blaxall; Bradford C Berk; Chen Yan
Journal:  Circulation       Date:  2005-05-02       Impact factor: 29.690

2.  Neurohumoral and inflammatory markers for prediction of right ventricular failure after implantation of a left ventricular assist device.

Authors:  Felix Hennig; Alexander V Stepanenko; Hans B Lehmkuhl; Marian Kukucka; Michael Dandel; Thomas Krabatsch; Roland Hetzer; Evgenij V Potapov
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-01-12

3.  Plasma osteoprotegerin, its correlates, and risk of heart failure: a prospective cohort study.

Authors:  Romina di Giuseppe; Ronald Biemann; Janine Wirth; Juliane Menzel; Berend Isermann; Gabriele I Stangl; Andreas Fritsche; Heiner Boeing; Matthias B Schulze; Cornelia Weikert
Journal:  Eur J Epidemiol       Date:  2016-06-15       Impact factor: 8.082

4.  AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure.

Authors:  Wei Wang; Ying Ou; Yanggu Shi
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

5.  [How do register data support clinical decision-making?].

Authors:  A Strangfeld; A Richter
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

Review 6.  Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart.

Authors:  Chen Yan; Clint L Miller; Jun-ichi Abe
Journal:  Circ Res       Date:  2007-03-02       Impact factor: 17.367

7.  Involvement of Cytokines in the Pathogenesis of Salt and Water Imbalance in Congestive Heart Failure.

Authors:  Zaher S Azzam; Safa Kinaneh; Fadel Bahouth; Reem Ismael-Badarneh; Emad Khoury; Zaid Abassi
Journal:  Front Immunol       Date:  2017-06-19       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.